{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:49:05Z","timestamp":1791251345325,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T00:00:00Z","timestamp":1648166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["17ck0106251h0001"],"award-info":[{"award-number":["17ck0106251h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["18ck0106251h0002"],"award-info":[{"award-number":["18ck0106251h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19ck0106251h0003"],"award-info":[{"award-number":["19ck0106251h0003"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20ck0106535h0001"],"award-info":[{"award-number":["20ck0106535h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21ck0106535h0002"],"award-info":[{"award-number":["21ck0106535h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["19cm0106562h0001"],"award-info":[{"award-number":["19cm0106562h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["20cm0106562h0002"],"award-info":[{"award-number":["20cm0106562h0002"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["21cm0106581h0001"],"award-info":[{"award-number":["21cm0106581h0001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17K09921"],"award-info":[{"award-number":["17K09921"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Patient-derived xenografts (PDX) are widely used as human cancer models. Previous studies demonstrated clonal discordance between PDX and primary cells. However, in acute myeloid leukemia (AML)-PDX models, the significance of the clonal dynamics occurring in PDX remains unclear. By evaluating changes in the variant allele frequencies (VAF) of somatic mutations in serial samples of paired primary AML and their PDX bone marrow cells, we identify the skewing engraftment of relapsed or refractory (R\/R) AML clones in 57% of PDX models generated from multiclonal AML cells at diagnosis, even if R\/R clones are minor at &lt;5% of VAF in patients. The event-free survival rate of patients whose AML cells successfully engraft in PDX models is consistently lower than that of patients with engraftment failure. We herein demonstrate that primary AML cells including potentially chemotherapy-resistant clones dominantly engraft in AML-PDX models and they enrich pre-existing treatment-resistant subclones.<\/jats:p>","DOI":"10.1038\/s41467-022-29304-6","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T07:03:05Z","timestamp":1648191785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9914-739X","authenticated-orcid":false,"given":"Naomi","family":"Kawashima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6024-6617","authenticated-orcid":false,"given":"Yuichi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Hui","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Ushijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akimi","family":"Akashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seara","family":"Ikeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Kihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Morishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Watamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6382-9498","authenticated-orcid":false,"given":"Hitoshi","family":"Kiyoi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,25]]},"reference":[{"key":"29304_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H Dohner","year":"2015","unstructured":"Dohner, H., Weisdorf, D. J. & Bloomfield, C. D. Acute Myeloid Leukemia. N. Engl. J. Med. 373, 1136\u20131152 (2015).","journal-title":"N. Engl. J. Med."},{"key":"29304_CR2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","volume":"29","author":"A Burnett","year":"2011","unstructured":"Burnett, A., Wetzler, M. & L\u00f6wenberg, B. Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 29, 487\u2013494 (2011).","journal-title":"J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol."},{"key":"29304_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H Dohner","year":"2017","unstructured":"Dohner, H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129, 424\u2013447 (2017).","journal-title":"Blood"},{"key":"29304_CR4","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","volume":"150","author":"JS Welch","year":"2012","unstructured":"Welch, J. S. et al. The origin and evolution of mutations in acute myeloid leukemia. Cell 150, 264\u2013278 (2012).","journal-title":"Cell"},{"key":"29304_CR5","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/nature13038","volume":"506","author":"LI Shlush","year":"2014","unstructured":"Shlush, L. I. et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature 506, 328\u2013333 (2014).","journal-title":"Nature"},{"key":"29304_CR6","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1126\/science.1164266","volume":"322","author":"CG Mullighan","year":"2008","unstructured":"Mullighan, C. G. et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Sci. (N. Y., N. Y.) 322, 1377\u20131380 (2008).","journal-title":"Sci. (N. Y., N. Y.)"},{"key":"29304_CR7","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding, L. et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 481, 506\u2013510 (2012).","journal-title":"Nature"},{"key":"29304_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1038\/nm.4410","volume":"23","author":"AA Ferrando","year":"2017","unstructured":"Ferrando, A. A. & Lopez-Otin, C. Clonal evolution in leukemia. Nat. Med. 23, 1135\u20131145 (2017).","journal-title":"Nat. Med."},{"key":"29304_CR9","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature22993","volume":"547","author":"LI Shlush","year":"2017","unstructured":"Shlush, L. I. et al. Tracing the origins of relapse in acute myeloid leukaemia to stem cells. Nature 547, 104\u2013108 (2017).","journal-title":"Nature"},{"key":"29304_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1479-7364-8-13","volume":"8","author":"L Rivina","year":"2014","unstructured":"Rivina, L., Davoren, M. & Schiestl, R. H. Radiation-induced myeloid leukemia in murine models. Hum. Genomics 8, 13 (2014).","journal-title":"Hum. Genomics"},{"key":"29304_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/ijms20020453","volume":"20","author":"M Almosailleakh","year":"2019","unstructured":"Almosailleakh, M. & Schwaller, J. Murine Models of Acute Myeloid Leukaemia. Int. J. Mol. Sci. 20, 453 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"29304_CR12","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1038\/onc.2008.16","volume":"27","author":"E McCormack","year":"2008","unstructured":"McCormack, E., Bruserud, O. & Gjertsen, B. T. Review: genetic models of acute myeloid leukaemia. Oncogene 27, 3765\u20133779 (2008).","journal-title":"Oncogene"},{"key":"29304_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler, J. J. et al. Patient-derived tumour xenografts as models for oncology drug development. Nat. Rev. Clin. Oncol. 9, 338\u2013350 (2012).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"29304_CR14","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas, D. & Hannon, G. J. Patient-derived tumor xenografts: transforming clinical samples into mouse models. Cancer Res. 73, 5315\u20135319 (2013).","journal-title":"Cancer Res."},{"key":"29304_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-015-0523-1","volume":"17","author":"JR Whittle","year":"2015","unstructured":"Whittle, J. R., Lewis, M. T., Lindeman, G. J. & Visvader, J. E. Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res. 17, 17 (2015).","journal-title":"Breast Cancer Res."},{"key":"29304_CR16","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/nature08989","volume":"464","author":"L Ding","year":"2010","unstructured":"Ding, L. et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 464, 999\u20131005 (2010).","journal-title":"Nature"},{"key":"29304_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms6871","volume":"5","author":"LV Nguyen","year":"2014","unstructured":"Nguyen, L. V. et al. DNA barcoding reveals diverse growth kinetics of human breast tumour subclones in serially passaged xenografts. Nat. Commun. 5, 5871 (2014).","journal-title":"Nat. Commun."},{"key":"29304_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature09650","volume":"469","author":"K Anderson","year":"2011","unstructured":"Anderson, K. et al. Genetic variegation of clonal architecture and propagating cells in leukaemia. Nature 469, 356\u2013361 (2011).","journal-title":"Nature"},{"key":"29304_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/nature09733","volume":"469","author":"F Notta","year":"2011","unstructured":"Notta, F. et al. Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells. Nature 469, 362\u2013367 (2011).","journal-title":"Nature"},{"key":"29304_CR20","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1084\/jem.20110105","volume":"208","author":"E Clappier","year":"2011","unstructured":"Clappier, E. et al. Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J. Exp. Med. 208, 653\u2013661 (2011).","journal-title":"J. Exp. Med."},{"key":"29304_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1126\/science.1227670","volume":"339","author":"A Kreso","year":"2013","unstructured":"Kreso, A. et al. Variable clonal repopulation dynamics influence chemotherapy response in colorectal cancer. Sci. (N. Y., N. Y.) 339, 543\u2013548 (2013).","journal-title":"Sci. (N. Y., N. Y.)"},{"key":"29304_CR22","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/nature13952","volume":"518","author":"P Eirew","year":"2015","unstructured":"Eirew, P. et al. Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature 518, 422\u2013426 (2015).","journal-title":"Nature"},{"key":"29304_CR23","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1038\/ng.3967","volume":"49","author":"U Ben-David","year":"2017","unstructured":"Ben-David, U. et al. Patient-derived xenografts undergo mouse-specific tumor evolution. Nat. Genet. 49, 1567\u20131575 (2017).","journal-title":"Nat. Genet."},{"key":"29304_CR24","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/leu.2016.166","volume":"31","author":"K Wang","year":"2017","unstructured":"Wang, K. et al. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia 31, 151\u2013158 (2017).","journal-title":"Leukemia"},{"key":"29304_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccr.2014.01.031","volume":"25","author":"JM Klco","year":"2014","unstructured":"Klco, J. M. et al. Functional heterogeneity of genetically defined subclones in acute myeloid leukemia. Cancer Cell 25, 379\u2013392 (2014).","journal-title":"Cancer Cell"},{"key":"29304_CR26","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1007\/s00432-018-2652-2","volume":"144","author":"M Culen","year":"2018","unstructured":"Culen, M. et al. The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice. J. Cancer Res. Clin. Oncol. 144, 1239\u20131251 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"29304_CR27","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.exphem.2017.12.002","volume":"59","author":"E Griessinger","year":"2018","unstructured":"Griessinger, E. et al. Acute myeloid leukemia xenograft success prediction: Saving time. Exp. Hematol. 59, 66\u201371 (2018). e64.","journal-title":"Exp. Hematol."},{"key":"29304_CR28","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng, S. W. et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature 540, 433\u2013437 (2016).","journal-title":"Nature"},{"key":"29304_CR29","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3324\/haematol.2016.153528","volume":"102","author":"AM Paczulla","year":"2017","unstructured":"Paczulla, A. M. et al. Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice. Haematologica 102, 854\u2013864 (2017).","journal-title":"Haematologica"},{"key":"29304_CR30","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1158\/2159-8290.CD-18-1453","volume":"9","author":"CM McMahon","year":"2019","unstructured":"McMahon, C. M. et al. Clonal selection with RAS pathway activation mediates secondary clinical resistance to selective FLT3 Inhibition in acute myeloid leukemia. Cancer Discov. 9, 1050\u20131063 (2019).","journal-title":"Cancer Discov."},{"key":"29304_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14106-0","volume":"11","author":"C Sand\u00e9n","year":"2020","unstructured":"Sand\u00e9n, C. et al. Clonal competition within complex evolutionary hierarchies shapes AML over time. Nat. Commun. 11, 579 (2020).","journal-title":"Nat. Commun."},{"key":"29304_CR32","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/leu.2015.165","volume":"29","author":"CC Smith","year":"2015","unstructured":"Smith, C. C., Lin, K., Stecula, A., Sali, A. & Shah, N. P. FLT3 D835 mutations confer differential resistance to type II FLT3 inhibitors. Leukemia 29, 2390\u20132392 (2015).","journal-title":"Leukemia"},{"key":"29304_CR33","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"29304_CR34","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/nature11183","volume":"487","author":"R Straussman","year":"2012","unstructured":"Straussman, R. et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500\u2013504 (2012).","journal-title":"Nature"},{"key":"29304_CR35","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1158\/0008-5472.CAN-15-0727","volume":"75","author":"JW Cassidy","year":"2015","unstructured":"Cassidy, J. W., Caldas, C. & Bruna, A. Maintaining tumor heterogeneity in patient-derived tumor xenografts. Cancer Res. 75, 2963\u20132968 (2015).","journal-title":"Cancer Res."},{"key":"29304_CR36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori, C. et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat. Med. 25, 603\u2013611 (2019).","journal-title":"Nat. Med."},{"key":"29304_CR37","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever, M. A. et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 15, 5323\u20135337 (2009).","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"key":"29304_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1182\/bloodadvances.2019000709","volume":"4","author":"Y Ishikawa","year":"2020","unstructured":"Ishikawa, Y. et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1-RUNX1T1 and CBFB-MYH11. Blood Adv. 4, 66\u201375 (2020).","journal-title":"Blood Adv."},{"key":"29304_CR39","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1038\/leu.2014.55","volume":"28","author":"R Kihara","year":"2014","unstructured":"Kihara, R. et al. Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 28, 1586\u20131595 (2014).","journal-title":"Leukemia"},{"key":"29304_CR40","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1080\/1042819021000040206","volume":"43","author":"K Osumi","year":"2002","unstructured":"Osumi, K. et al. Rapid screening of leukemia fusion transcripts in acute leukemia by real-time PCR. Leuk. Lymphoma 43, 2291\u20132299 (2002).","journal-title":"Leuk. Lymphoma"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29304-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29304-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T11:39:20Z","timestamp":1669289960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-29304-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,25]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["29304"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-29304-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,25]]},"assertion":[{"value":"13 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H. Kiyoi received research funding from FUJIFILM Corporation, Kyowa Hakko Kirin Co., Ltd., Bristol-Myers Squibb, Otsuka Pharmaceutical Co., Ltd., Perseus Proteomics Inc., Daiichi Sankyo Co., Ltd., Abbvie Inc., CURED Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Zenyaku Kogyo Co., Ltd., Nippon Shinyaku Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novartis Pharma K.K., Sanofi K.K., and Pfizer Japan Inc., and honoraria from Bristol-Myers Squibb, Astellas Pharma Inc., and Novartis Pharma K.K. The remaining authors declare no competing interests. All other authors have no competing non-financial interests to declare.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1624"}}